$253 Million! This Canadian Medical Fiber Optic Sensor Maker Will Be Acquired

Haemonetics Corporation, a company focused on providing innovative medical solutions with proprietary optics, recently announced that the company has entered into a definitive agreement. Under the agreement, Haemonetics will acquire all of the outstanding shares of OpSens, a Canadian fiber optic sensor manufacturer, at a price of C$2.90 per share.
This is an all-cash transaction, with a fully diluted equity value of approximately $253 million at current exchange rates.The OpSens board of directors unanimously approved the transaction, subject to shareholder and regulatory approvals. The acquisition is expected to close by the end of January 2024.
Optical Technology Interventional Cardiology
OpSens provides commercially and clinically validated optical technologies primarily for use in interventional cardiology.OpSens' core products include SavvyWire®, the world's first and only sensor-guided 3-in-1 guidewire for use in TAVR procedures, which acts as a pacemaker and a pressure monitoring wire, advancing the workflow of the procedure and potentially shortening the patient's hospital stay.
It produces and manufactures pressure guidewire sensors that improve clinical outcomes by accurately and consistently measuring fractional flow reserve (FFR) and diastolic pressure ratio (dPR) to help clinicians diagnose and treat patients with coronary artery disease.
In addition, OpSens produces a range of fiber optic sensor solutions for medical devices and other critical industrial applications. Its flagship product, OptoWire, uses optical coherence tomography (OCT) to diagnose the severity of coronary artery stenosis and guide treatments such as angioplasty.
Stewart Strong, President of Global Hospitals at Haemonetics, said, "With the acquisition of OpSens, we have expanded our leadership position in interventional cardiology and strengthened our foundation for further growth and diversification. By leveraging OpSens' proprietary optical sensor technology, our global commercial infrastructure, and our relationships with top U.S. hospitals performing TAVR and PCI procedures, we have a powerful opportunity to raise the standard of care for more physicians and patients worldwide. We are excited to welcome the talented team at OpSens and look forward to advancing our shared commitment to maximizing patient benefit and value for our customers."
Fiber optic sensing as a breakthrough
Expanding the hospital business unit portfolio with innovative fiber optic sensor technology has become a breakthrough in the attractive interventional cardiology market.OpSens has a strong competitive advantage with its portfolio of products used in TAVR and PCI solutions, with a total target market of approximately $1 billion.OpSens' technology is also used in a range of healthcare and industrial applications, representing a growth and additional avenues for diversification. Going forward, the two companies plan to strengthen their collaboration in the following areas:
leverage Haemonetics' commercial and geographic deployments to accelerate adoption.The OpSens portfolio has proven commercial success and is well positioned for long-term growth.Haemonetics' commercial success with its VASCADE® vascular closure portfolio, combined with extensive existing commercial and clinical infrastructure, will accelerate customer access to OpSens products , and has the potential to position SavvyWire as the leading lead wire for TAVR procedures in the United States. In addition, Haemonetics' strength in high-growth international markets will enable further penetration of OpSens products into these regions.
Long-term growth through additional product and market expansion opportunities Haemonetics plans to build on the OpSens acquisition and further expand its hospital business through internal and external research and development, clinical and other business development efforts. Over the past several quarters, Haemonetics has made additional strategic investments that will further complement OpSens' product portfolio and strengthen Haemonetics' business strength in interventional cardiology.